IGF‐I and testosterone levels as predictors of bone mineral density in healthy, community‐dwelling men

Rucker, Diana; Ezzat, Shereen; Diamandi, Anastasia; Khosravi, Javad; Hanley, David A.

doi:10.1111/j.1365-2265.2004.02006.x

Cited by 55 publications

(34 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In young and middle-aged men, 25OHD was weakly correlated positively with BMD at the lumbar spine and the hip (13). The relationship between the PTH level and the BMD in young and middle-aged adults was weak or non-significant (15,29,30). Thus, current PTH secretion does not seem to be a significant determinant of bone mass and microarchitecture in young adult men, although these men may be in the phase of slow bone loss (31).…”

Section: Discussionmentioning

confidence: 99%

Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study

Chaitou

Boutroy²,

Vilayphiou³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: In the elderly, vitamin D deficit, low calcium intake, and impaired bone microarchitecture are associated with higher risk of hip fracture. We assessed the association of bone microarchitecture with calcium intake and serum concentrations of 25-hydroxycholecalciferol (25OHD) and parathyroid hormone (PTH) in men. Design: Cross-sectional analysis was performed in 1064 men aged 20-87 years not taking vitamin D or calcium supplements. Methods: Daily calcium intake was assessed using a food frequency questionnaire. Bone microarchitecture was assessed at distal radius and tibia by high-resolution peripheral quantitative computed tomography. We measured serum and urinary levels of biochemical bone turnover markers (BTMs). Statistical models were adjusted for age, weight, height, and glomerular filtration rate. Results: In 500 men aged !65 years, lower 25OHD levels and low calcium intake were associated with lower trabecular volumetric bone mineral density (Dtrab) at the distal tibia, due to lower trabecular number (Tb.N). Low calcium intake was associated with lower cortical thickness (Ct.Th). Higher PTH level was associated with higher BTM levels. In 563 men aged R65 years, the highest PTH quartile was associated with lower Ct.Th (tibia), lower Dtrab (both sites), and lower Tb.N (radius) compared with the lowest quartile. Low calcium intake was associated with lower Tb.N and more heterogenous trabecular distribution. BTM positively correlated with the PTH concentration. Conclusion: In older men, elevated PTH concentration is associated with high bone turnover, poor trabecular microarchitecture (radius and tibia), and, at the distal tibia, lower Ct.Th. Low calcium intake is associated with lower Tb.N and more heterogenous trabecular distribution.European Journal of Endocrinology 165 151-159

show abstract

Section: Discussionmentioning

confidence: 99%

Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study

Chaitou

Boutroy²,

Vilayphiou³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Low-serum IGF levels decrease osteoblast proliferation and bone matrix formation and reduce the activation of osteoclasts (29). Several studies have demonstrated a positive correlation between the BMD of the lumbar spine and the IGF-I concentration (30). It is well documented that the GH-IGF axis is defective in TM.…”

Section: Acquired Factorsmentioning

confidence: 99%

Bone Disease in Haemoglobin Disorders

Voskaridou

Terpos

2013

Thalassemia Reports

View full text Add to dashboard Cite

Bone disease represents a prominent cause of morbidity in patients with thalassaemia and other haemoglobin disorders. The delay in sexual maturation, the presence of diabetes and hypothyroidism, the parathyroid gland dysfunction, the haemolytic anaemia, the progressive marrow expansion, the iron toxicity on osteoblasts, the iron chelators, and the deficiency of growth hormone or insulin growth factors have been identified as major causes of osteoporosis in thalassaemia. Adequate hormonal replacement, effective iron chelation, improvement of hemoglobin levels, calcium and vitamin D administration, physical activity, and smoking cessation are the main to-date measures for the management of the disease. During the last decade, novel pathogenetic data suggest that the reduced osteoblastic activity, which is believed to be the basic mechanism of bone loss in thalassemia, is accompanied by a comparable or even greater increase in bone resorption. Therefore, potent inhibitors of osteoclast activation, such as the aminobisphosphonates, arise as key drugs for the management of osteoporosis in thalassaemia patients and other haemoglobin disorders.

show abstract

“…A number of epidemiological studies have found that bone mineral density in the aging male population is positively associated with endogenous androgen levels (Murphy et al 1993;Ongphiphadhanakul et al 1995;Rucker et al 2004). Testosterone levels in young men have been shown to correlate with bone size, indicating a role in determination of peak bone mass and protection from future osteoporosis (Lorentzon et al 2005).…”

Section: Effects On Bone and Osteoporosismentioning

confidence: 99%

Testosterone for the aging male; current evidence and recommended practice

Stanworth

Jones²

2008

CIA

123

View full text Add to dashboard Cite

An international consensus document was recently published and provides guidance on the diagnosis, treatment and monitoring of late-onset hypogonadism (LOH) in men. The diagnosis of LOH requires biochemical and clinical components. Controversy in defi ning the clinical syndrome continues due to the high prevalence of hypogonadal symptoms in the aging male population and the non-specifi c nature of these symptoms. Further controversy surrounds setting a lower limit of normal testosterone, the limitations of the commonly available total testosterone result in assessing some patients and the unavailability of reliable measures of bioavailable or free testosterone for general clinical use. As with any clinical intervention testosterone treatment should be judged on a balance of risk versus benefi t. The traditional benefi ts of testosterone on sexual function, mood, strength and quality of life remain the primary goals of treatment but possible benefi cial effects on other parameters such as bone density, obesity, insulin resistance and angina are emerging and will be reviewed. Potential concerns regarding the effects of testosterone on prostate disease, aggression and polycythaemia will also be addressed. The options available for treatment have increased in recent years with the availability of a number of testosterone preparations which can reliably produce physiological serum concentrations.

show abstract

IGF‐I and testosterone levels as predictors of bone mineral density in healthy, community‐dwelling men

Abstract: These data support the hypothesis that the age-related decline in bone mass in men is associated with declining levels of IGF-I and testosterone.

Cited by 55 publications

References 46 publications

Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study

Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study

Bone Disease in Haemoglobin Disorders

Testosterone for the aging male; current evidence and recommended practice

Contact Info

Product

Resources

About